(Q40405411)

English

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations

scientific article published on July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations (English)

1 reference

Europe PubMed Central

20 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Joanna K Law

1

1 reference

Europe PubMed Central

20 September 2017

Jin K Ho

2

1 reference

Europe PubMed Central

20 September 2017

Paul J Hoskins

3

1 reference

Europe PubMed Central

20 September 2017

Siegfried R Erb

4

1 reference

Europe PubMed Central

20 September 2017

Urs P Steinbrecher

5

1 reference

Europe PubMed Central

20 September 2017

Eric M Yoshida

6

1 reference

Europe PubMed Central

20 September 2017

publication date

1 July 2005

1 reference

Europe PubMed Central

20 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

20 September 2017

46

1 reference

Europe PubMed Central

20 September 2017

7

1 reference

Europe PubMed Central

20 September 2017

1085-1089

1 reference

Europe PubMed Central

20 September 2017

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine

1 reference

https://api.crossref.org/works/10.1080%2F10428190500062932

21 January 2018

Identifiers

10.1080/10428190500062932

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40405411&oldid=1897076120"